Artificial intelligence is working its way through the pharmaceutical industry on two very different fronts — how drugs are discovered and how they are made and packaged.
According to a press release carried by USA Today, Linuo Pharmaceutical Packaging Co., Ltd. was invited to speak at the Third Global Expansion Summit, held at Resorts World Sentosa in Singapore from June 28 to 29. The company framed its message around a shift "from products to solutions," charting what it calls a new global path built on AI-driven intelligent manufacturing. In plain terms, a firm known for making the vials, containers and packaging that hold medicines is repositioning itself around smarter, AI-enabled production rather than physical goods alone.
On the discovery side, ETPharma.com reported, via Google News, that Mankind has signed an AI drug discovery pact with Denovo Sciences. Such partnerships typically pair a drugmaker's development pipeline with a specialist's AI tools to help identify and design promising drug candidates faster than traditional lab work allows.
The two items are separate deals from different players, but together they sketch a broader pattern: AI is no longer confined to one corner of the pharmaceutical business. It is being pitched as a tool for the earliest stage of a medicine's life — finding a molecule worth pursuing — and for one of the last — manufacturing and packaging the finished product at scale.
Both stories come from company-sourced announcements, so the concrete results remain to be seen. Neither source details cost savings, timelines or specific technologies used.
Why it matters: medicines reach patients faster and cheaper only if both ends of the pipeline — discovery and manufacturing — get more efficient, and these moves signal that pharma is betting AI can deliver on both.